Cockayne syndrome (CS) is classically recognized by its hallmark features: progressive neurodegeneration, cachectic dwarfism, and a progeroid (prematurely aged) appearance. However, the clinical presentation of CS is highly heterogeneous, often leading to significant diagnostic challenges. Recent research focusing on ERCC8-related Cockayne syndrome (also known as CSA) has shed new light on the phenotypic spectrum of the disease, revealing critical overlaps with other neurological conditions and identifying novel markers of disease progression.
The Diagnostic Challenge: Differentiating CS from Cerebral Palsy
One of the most significant findings in recent clinical analyses is the frequent misdiagnosis of early-onset CSA as cerebral palsy (CP). In a retrospective study of pediatric patients with confirmed ERCC8 variants, all individuals initially presented with early-onset motor delay and spasticity—symptoms that strongly mimic CP.
This clinical overlap is particularly pronounced in the early stages of the disease, before the more classic features of CS, such as severe growth failure and the characteristic facial phenotype, become apparent. The misdiagnosis of CS as CP can delay appropriate medical management, genetic counseling, and the implementation of targeted supportive therapies.
This highlights the indispensable role of early and comprehensive genetic testing, such as whole-exome sequencing (WES), in pediatric patients presenting with unexplained motor delays and spasticity. Accurate genetic diagnosis not only confirms the presence of CS but also allows for the stratification of the disease into its respective subtypes (CS I, II, or III), which is crucial for prognostic discussions with families.
Hepatic Dysfunction as a Biomarker of Severity
Beyond refining the diagnostic process, recent studies have also sought to identify reliable biomarkers that correlate with disease severity and progression. Interestingly, hepatic (liver) dysfunction has emerged as a significant indicator in CSA-related CS.
While CS is primarily considered a neurodegenerative and developmental disorder, the underlying defect in transcription-coupled nucleotide excision repair (TC-NER) affects multiple organ systems. Clinical data indicates that elevated serum transaminases—markers of liver stress or damage—are frequently observed in patients with CS. More importantly, the severity of hepatic dysfunction appears to correlate with the overall severity of the disease phenotype and worsens as the disease progresses.
Monitoring hepatic function may therefore serve as a valuable, non-invasive biomarker for tracking disease trajectory. This finding underscores the need for a multidisciplinary approach to CS management, incorporating regular hepatology evaluations alongside neurological and developmental assessments.
Expanding the Clinical Phenotype
In addition to highlighting the CP-like presentation and hepatic involvement, recent analyses have expanded the known clinical phenotype of CSA. For example, some patients have been documented presenting with anhidrosis (the inability to sweat normally), a rarely reported dermatological manifestation in CS. Furthermore, the development of severe Achilles tendon contractures has been noted as a common musculoskeletal complication, emphasizing the critical need for early and systematic rehabilitation therapy to maintain mobility and quality of life.
In summary, our understanding of ERCC8-related Cockayne syndrome is evolving. By recognizing the early clinical overlap with cerebral palsy, utilizing genetic testing for definitive diagnosis, and monitoring systemic markers like hepatic function, clinicians can provide more accurate diagnoses and comprehensive care for individuals affected by this complex disorder.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.